- Accueil >
- Publications >
- International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers
International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers
Auteurs
Jennifer J. Mueller, Henrik Lajer, Berit Jul Mosgaard, Slim Bach Hamba, Philippe Morice, Sebastien Gouy, Yaser Hussein, Robert A. Soslow, Brooke A. Schlappe, Qin C. Zhou, Alexia Iasonos, Claus Høgdall, Alexandra Leary, Roisin E. O’Cearbhaill, Nadeem R. Abu-Rustum
Résumé
Objective
We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes.
Methods
This was a retrospective review spanning 1976–2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed.
Results
Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy—55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%–85%) for patients with stage I to II disease and 17% (95% CI, 8%–29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%–86%) for patients who underwent fertility-preserving surgery.
Conclusions
Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.